Brief: Neurizon Therapeutics Gets EMA's Positive Opinion On Orphan Medicinal Product Designation For NUZ-001
11/11/2024 07:16
Nov 11 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX :
* NEURIZON THERAPEUTICS RECEIVES POSITIVE OPINION ON ORPHAN MEDICINAL
PRODUCT
DESIGNATION FOR NUZ-001 IN EUROPE
Source text: ID:nPreGmh0Xa
Further company coverage: NUZ.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility